Evaluation of selected biochemical parameters in the serum of rats pretreated with simvastatin, doxepin or their combination
DOI:
https://doi.org/10.12923/Keywords:
simvastatin, doxepin, biochemical parametersAbstract
The aim of this study was to estimate the influence of 14-day simultaneous i.p. adminiatration of simvastatin and doxepin on some biochemical parameters indicating liver function in rats. The activity of AST, ALT and the concentration of total protein and α-fetoprotein was determined. The results show that 14-day combined application with simvastatin and doxepin causes the increase of transaminases activities and AFP level but the decrease of total protein in comparison to the groups receiving these drugs individually. It seems that the combined treatment with simvastatin and doxepin is possible on the condition of the regular control of parameters indicating liver function. These data can be helpful in the treatment with these drugs.
References
Boottorf M.: Statin safety and drug interactions: clinical implications. Am J Cardiol, C27, 97, 2006.
2. Bottorf M.: “Fire and forget?” – pharmacological considerations in coronary care. Artherosklerosis, 23, 147, 1999.
3. Chalasani N.: Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology, 41, 690, 2005.
4. Charles E.C.et al.: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med, 618, 118, 2005.
5. Chug E., Nafziger A. N., Kazierad D. J., Bertino J. S.: Pharmacokinetic and drug disposition. Comparison of midazolam and simvastatin as cytochrome P450 3A probes, Clinical Pharmacology and Therapeutics, 79, 350,2006.
6. Cohen D.E. et al.: An Assessment of Statin Safety by Hepatologists. Am J Cardiol, S77, 97, 2006.
7. Cohen D.E. et al.: An Assessment of Statin Safety by Hepatologists. Am J Cardiol, S77, 97, 2006.
8. Downs J.R. et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc, 1615, 279, 1998.
9. Dujovne C. A.: Side effects of statins: hepatis versus „transaminitis” – myositis versus „CPKitis”. Am J Card, 1411, 89, 2002.
10. Hawton K. et al.: Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. B J Psych, 196, 354, 2010.
11. Heerey A. et al.: The potential for drug interaction with statin therapy In Ireland. Ir J Med Sci, 176, 3, 2003.
12. Herman R.J.: Drug interactins and the statins. CMAJ, 161 9100, 1281, 1999.
13. Jacobson T.A.: Statin Safety: Lessons from New Drug Applications for Marketed Statins. Am J Cardiol, 97, S44, 2006.
14. Karnik N.S., Maldonado J.R.: Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics, 565, 46, 2005.
15. Kiortisis D. N. et al.: Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis, 7, 195, 2007.
16. Lakshmanan M., et al.: Effective low dose tricyclic antidepressant treatment for depressed geriatric rehabilitation patients: A double-blind study. Journal of the American Geriatrics Society, 421, 6, 1986.
17. Mach T.: Statyny a ryzyko uszkodzenia wątroby. Przegląd Gastroenterologiczny, 111, 2, 2007.
18. Mahley R.W., Bersot T.P.: Drug therapy for hypercholesterolemia and dyslipidemii. In: Goodman, Gilman, editors. The pharmacological basic of therapeutics, Medical Publishing Division, 971, 2001.
19. Marttila M. et al.: A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol, 441, 5, 1995.
20. Mitchell D.B., Acosta D.: Evaluation of the cytotoxicity of tricyclic antidepressant in primary cultures of rat hepatocytes. J. Toxicol. Environ. Health, 7, 83, 1981.
21. Paoletti R., Corsini A., Bellosta S.: Pharmacological interaction of statins. Atherosclerosis, (Suppl. 3), 35, 2002.
22. Patassini S., Giampa C., Martorana A., Bernardi G., Cusco FR.: Effect of simvastatin on neurorotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington´s disease, Neurosci Lett, 19, 166, 2008.
23. Rudorfer M.V. et al.: Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety, 18, 10, 1994.
24. Smith C. et al.: Screening for Statin-Related Toxicity: The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting. Arch Intern Med, 688, 163, 2003.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
